Literature DB >> 10672954

Relationship between HLA-DR antigen and HLA-DRB1 alleles and prostate cancer in Japanese men.

H Azuma1, M Sada, T Tsuji, H Ueda, Y Katsuoka.   

Abstract

PURPOSE: Human leukocyte antigens (HLA) are cell surface glycoproteins playing a key role in the immune system. In some cancers, changes in major histocompatibility complex (MHC) class I and II expression, usually a reduction or loss of these molecules, appear to provide a mechanism whereby tumour cells may escape host immunity. We investigated the relationship between HLA, especially class II, molecules and prostate cancer in Japanese men using molecular techniques.
MATERIALS AND METHODS: HLA class II typing was performed by the polymerase chain reaction-sequence specific primer (PCR-SSP) method of analysis and/or a commercial rapid assay based on the PCR followed by reverse dot-blot hybridization of the PCR products (Inno-LiPA assay). Allele frequencies were calculated. HLA allele frequencies reported in 1216 healthy Japanese individuals were used as the control data. Differences in allele frequency between subjects and the control group were analyzed by the chi-square test. The relationship between HLA antigens/alleles and prostate cancer is expressed in terms of relative risk (RR).
RESULTS: The frequencies of HLA-DR4 were significantly higher in Japanese men with prostate cancer than in the healthy control group (gene frequency 36.2% vs. 26.3% in control, p<0.05), although the relative risk of prostate cancer was less than 2. Furthermore, the frequencies of HLA-DRB1-0406, 0410 and 1405 allele were significantly higher in the prostate cancer group than in the control group (allele frequency was 7.3%, 4.5% and 5.4% vs. 3.03%, 1.79% and 2.22%, p<0.05, respectively). RR of those HLA-DRB1 allele for prostate cancer was 2.6 in each allele.
CONCLUSIONS: HLA molecules may be useful for the early detection of prostate cancer as a risk factor, and also for recognizing cancer activity by using them as a marker helpful in the choice of appropriate treatment by predicting prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672954     DOI: 10.1023/a:1007126219791

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

1.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation.

Authors:  O Olerup; H Zetterquist
Journal:  Tissue Antigens       Date:  1992-05

2.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

3.  Familial lymphoproliferative malignancy: clinical and laboratory follow-up.

Authors:  W A Blattner; J H Dean; J F Fraumeni
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

4.  HL-A antigens in solid tumors.

Authors:  M Takasugi; P I Terasaki; B Henderson; M R Mickey; H Menck; R W Thompson
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

5.  HLA antigens and germ-cell tumours.

Authors:  P Aiginger; R Kuzmits; C Kratzig; H P Schwarz; C C Zielinski; J Kühböck; W R Mayr
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

6.  HLA type and survival in lung cancer.

Authors:  G B Weiss; L B Nawrocki; J C Daniels
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

7.  Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.

Authors:  B H Xue; Y Zhang; J A Sosman; D J Peace
Journal:  Prostate       Date:  1997-02-01       Impact factor: 4.104

8.  Survival and the HL-A system in acute lymphoblastic leukaemia.

Authors:  S D Lawler; P T Klouda; P G Smith; M M Till; R M Hardisty
Journal:  Br Med J       Date:  1974-03-23

9.  Human leukocyte antigen subtype analysis in patients with advanced adenocarcinoma of the prostate.

Authors:  A Akdaş; L Türkeri; Y Alican; F Simşek; T Akoğlu
Journal:  Prostate       Date:  1994       Impact factor: 4.104

10.  HLA and prognostic factors in primary breast cancer.

Authors:  R V Iaffaioli; M Maio; G Ruggiero; M De Felice; A Ungaro; L Del Vecchio; G B Rosato; A R Bianco; S Zappacosta
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

View more
  1 in total

1.  HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson's disease in Chinese Han population.

Authors:  Congcong Sun; Lei Wei; Feifei Luo; Yi Li; Jiaobiao Li; Feiqi Zhu; Ping Kang; Rensi Xu; Lulu Xiao; Zhuolin Liu; Pingyi Xu
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.